Please use this identifier to cite or link to this item:
Title: Efficacy of vemurafenib in hairy-cell leukemia
Authors: Samuel, Jesvin
Macip, Salvador
Dyer, Martin J. S.
First Published: 16-Jan-2014
Publisher: Massachusetts Medical Society
Citation: New England Journal of Medicine, 2014, 370 (3), pp. 286-288
Abstract: The BR A F V600E mutation is present in nearly all cases of hairy-cell leukemia. 1 This finding has led to the introduction of BRAF inhibitors for the treatment of chemotherapy-re - sistant hairy-cell leukemia, and patients have had a good response to the oral inhibitor vemu - rafenib. 2-4 Constitutive phosphorylation of both extracellular signal-regulated kinase (ERK) and mitogen-activated protein–ERK kinase (MEK) has been considered to be a direct consequence of BRAF activation, with BRAF inhibition result - ing in cell death through suppression of this pathway in hairy-cell leukemia. However, data to support this theory are limited, since most pa - tients present with pancytopenia. [Opening paragraph]
DOI Link: 10.1056/NEJMc1310849
ISSN: 0028-4793
eISSN: 1533-4406
Version: Publisher Version
Status: Peer-reviewed
Type: Journal Article
Rights: Copyright © 2014, Massachusetts Medical Society. Deposited with reference to the publisher’s archiving policy available on the SHERPA/RoMEO website.
Appears in Collections:Published Articles, Dept. of Biochemistry

Files in This Item:
File Description SizeFormat 
nejmc1310849.pdfPublished (publisher PDF)502.98 kBAdobe PDFView/Open

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.